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“If I had a world of my own, everything would be nonsense. Nothing would be what it 
is, because everything would be what it isn't. And contrary wise, what is, it wouldn't 
be. And what it wouldn't be, it would. You see?” 
Lewis Carroll 
(English writer, 1832-1898) 
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Abstract 
Premature termination codons (PTCs or nonsense codons) can arise from various types 
of mutations in germ or somatic cells. PTCs promote premature translational 
termination and the induction of nonsense-mediated mRNA decay (NMD). NMD is a 
surveillance system that prevents the synthesis of C-terminally truncated proteins toxic 
for the cell. The physiological importance of NMD is manifested by the fact that about 
one third of genetic disease-associated mutations generate PTCs. 
In recent years, a novel therapeutic approach called suppression therapy has been 
developed that utilizes low molecular weight compounds to induce the translation 
machinery to recode a PTC into a sense codon. Beta-thalassaemia (β-thalassaemia) is 
one of the most common genetic diseases worldwide, and nonsense mutations 
occurring in the beta-globin (β-globin) are among the most frequent mutations 
associated with β-thalassaemia. Some studies have shown that aminoglycosides, low 
molecular weight compounds, and non-aminoglycosides can suppress PTCs in cystic 
fibrosis and Duchenne’s muscular dystrophy, but it remains unclear whether β-
thalassaemia would also be responsive to a similar drug treatment. Preliminary results 
obtained in our lab have shown that the aminoglycoside G418 can suppress a 
nonsense mutation at codon 39 of the human β-globin mRNA, although at low levels in 
cultured erythroid cells. To investigate if suppression therapy can restore enough β-
globin protein to correct the disease manifestations of β-thalassaemia, we tested 
whether G418 is able to induce efficient levels of suppression in a dose-dependent and 
time-course manner in HeLa cells transfected with plasmids containing the human β-
globin wild type gene (βWT) or the counterpart carrying a nonsense mutation at codon 
39 (β39).  
Our results show a slight increase in the levels of mRNA of the β39 transcript which 
may indicate a possible effect by the drug. Seen as we were unable to test the effect of 
the drug on a protein level, in the future, it would be of great interest to evaluate its 
effect on protein expression levels. 
Key-words: Nonsense-mediated mRNA decay (NMD); mRNA translation; genetic 
diseases; suppression therapy; G418. 
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Sumário 
Algumas das mutações que ocorrem em células somáticas ou na linha germinal podem 
resultar na formação de codões de terminação prematura da tradução (CTPs ou 
codões nonsense). Um terço das mutações associadas a doenças genéticas resulta na 
produção de CTPs. Em geral, a introdução dum CTP num transcrito induz a terminação 
prematura da tradução e a activação do mecanismo de decaimento do mRNA mediado 
por mutações nonsense (nonsense-mediated mRNA decay; NMD). O NMD é um 
mecanismo de controlo de qualidade que impede a produção de proteínas truncadas 
na extremidade C-terminal tóxicas para a célula.  
No decorrer dos últimos anos, tem sido desenvolvida uma nova terapia, designada 
como terapia de supressão, que utiliza compostos de baixo peso molecular para 
induzir a maquinaria de tradução a alterar um CTP para um codão sense. O objectivo 
da terapia de supressão é estimular a capacidade de competição de tRNAs aminoacil 
com o complexo de terminação para a ligação ao CTP no local A do ribossoma, de 
forma a suprimir especificamente a terminação em CTPs e não em codões de 
terminação naturais. Embora a talassémia seja uma das doenças genéticas mais 
comuns e as mutações nonsense no gene da beta-globina (β-globina) estejam muito 
frequentemente associadas à beta-talassémia (β-talassémia), a utilização da terapia de 
supressão nestes casos ainda não foi investigada de forma detalhada. Resultados 
preliminares obtidos pelo nosso laboratório indicam que o aminoglicósido G418 tem a 
capacidade de suprimir uma mutação nonsense no codão 39 do mRNA da β-globina, 
em células eritróides em cultura. De forma a confirmar o princípio de que a terapia de 
supressão pode restaurar os níveis de β-globina, testámos se o composto G418 tem a 
capacidade de induzir níveis significativos de supressão em células HeLa transfectadas 
com plasmídeos que contêm o gene da β-globina humana normal (βWT) ou o 
equivalente com mutação nonsense no codão 39 (β39). 
Segundo os resultados obtidos, há um ligeiro aumento nos níveis de transcrito β39 o 
que pode ser indicador de um possível efeito da droga. Como não nos foi possível 
verificar o efeito da droga nos níveis de proteína é necessário trabalho futuro para 
avaliar o seu efeito nos níveis de expressão proteica. 
Palavras-chave: Decaimento do mRNA mediado por mutações nonsense (NMD); 
tradução do mRNA; doenças genéticas; terapia de supressão; G418. 
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I. Introduction 
Eukaryotic gene expression pathway involves a series of interconnected steps, from 
transcription to translation. These steps are integrated with one another to augment 
the efficiency and fidelity of gene expression. This allows expression of individual 
genes to be controlled, producing transcripts and eventually detecting and degrading 
aberrant transcripts (Chang et al, 2007; Clancy & Brown, 2008; Nicholson et al, 2010; 
Behm-Ansmant et al, 2007). If not detected and degraded, these transcripts can result 
in the accumulation of potentially harmful truncated proteins (Nicholson et al, 2010). 
Given the complex chain of biochemical reactions involved in transforming the genetic 
information of an organism into gene products, the overall accuracy of gene 
expression is quite astonishing (Mühlemann & Lykke-Andersen, 2010). Since mRNAs 
function primarily as templates for protein synthesis, it is now established that most, if 
not all, of the steps of the gene expression pathway can be regulated by quality-
control mechanisms (or mRNA surveillance mechanisms) both in the nucleus and in the 
cytoplasm at multiple stages during gene expression. For example, improperly 
processed mRNAs are degraded by mRNA surveillance mechanisms in the nucleus 
before they are exported. In the cytoplasm, quality control mechanisms assess the 
translatability of the mRNA and degrade any that lacks translation termination codons 
or that has premature translation termination codons (PTCs), thereby preventing the 
accumulation of potentially toxic protein fragments (Schoenberg & Maquat, 2012; 
Behm-Ansmant et al, 2007; Nicholson et al, 2010). Nonsense-mediated mRNA decay 
(NMD) represents a translation-dependent post-transcriptional process that selectively 
recognizes and degrades mRNAs whose open reading frame (ORF) is truncated by a 
PTC. In doing so, NMD protects the cell from accumulating C-terminally truncated 
proteins with potentially deleterious functions (Mühlemann et al, 2008). 
NMD acts not only on aberrant mRNAs, but also regulates the expression of naturally 
occurring transcripts having features that allow them to be recognized as PTC-
containing transcripts. In this way, NMD also contributes to the post-transcriptional 
regulation of gene expression (Behm-Ansmant et al, 2007). 
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I.1. mRNA translation 
In order to understand how and when the surveillance mechanisms can act, we need 
to understand the pathway of gene expression in further detail. One of the most 
important steps in this pathway is the translation of proteins from messenger RNA 
(mRNA). Regulation of translation is a mechanism that is used to modulate gene 
expression in a wide range of biological situations. From early embryonic development 
to cell differentiation and metabolism, translation regulation is used to fine-tune 
protein levels in both time and space (Gebauer & Hentze, 2004).  
During translation, the sequence of codons on mRNA directs the synthesis of a 
polypeptide chain. This dynamic process is usually divided into three phases: initiation, 
elongation and termination (Preiss & Hentze, 2003; Ramakrishnan, 2002). Ribosomes, 
large ribonucleoprotein particles composed of two subunits in all species, are, along 
with numerous translation factors, the cellular machines responsible for translating 
genetic information into polypeptide sequences. During the step-wise movement of an 
mRNA through the ribosome, amino acids are incorporated into the elongating 
polypeptide chain. Each subunit has three binding sites for tRNA, designated: the A 
(aminoacyl), which accepts the incoming aminoacylated tRNA; P (peptidyl), which 
holds the tRNA with the nascent peptide chain; and E (exit), which holds the 
deacylated tRNA before it leaves the ribosome. The fidelity of amino acids 
incorporation depends on base-pair complementarities between sense codons and 
anticodons of aminoacyl-tRNAs (Korostelev, 2011; Ramakrishnan, 2002). We will 
discuss the three phases of translation in the following paragraphs. 
 
I.1.1.Translation initiation  
The translation of mRNA begins with the formation of the ternary complex composed 
of eukaryotic initiation factor 2 (eIF2), a hetero-dimer of 3 subunits (α, β and γ), bound 
to the methionyl-initiator tRNA (Met-tRNAi
Met), and GTP by the γ subunit (fig 1. A) 
(Gebauer & Hentze, 2004). Once the ternary complex is assembled and active, it must 
bind to the 40S ribosomal subunit. This binding is aided by eukaryotic initiation factors 
1, 1A, 3 and 5. The structure resulting from the bound of ternary complex to 40S 
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ribosomal subunit alongside initiation factors 1, 1A, 3 and 5 is designated 43S pre-
initiation complex (fig 1. B) (Gebauer & Hentze, 2004; Jackson et al, 2010).  
Figure 1: Cap-mediated translation initiation. The methionine-loaded initiator tRNA binds to 
GTP-coupled eIF2, to yield the ternary complex. This complex then binds to the small (40S) 
ribosomal subunit, eIF3 and other initiation factors to form the 43S pre-initiation complex. The 
pre-initiation complex recognizes the mRNA by the binding of eIF3 to the eIF4G subunit of the 
cap-binding complex. In addition to eIF4G, the cap-binding complex contains eIF4E, which 
directly binds to the cap, and eIF4A, an RNA helicase that unwinds secondary structure during 
the subsequent step of scanning. The 43S pre-initiation complex scans the mRNA in a 5′ to 3′ 
direction until it identifies the initiator codon AUG. Scanning is assisted by the factors eIF1 and 
eIF1A. Stable binding of the 43S pre-initiation complex to the AUG codon yields the 48S 
initiation complex. Subsequent joining of the large (60S) ribosomal subunit results in the 
formation of the 80S initiation complex. Both AUG recognition and joining of the large 
ribosomal subunit trigger GTP hydrolysis on eIF2 and eIF5B, respectively. Subsequently, the 
80S complex is competent to catalyze the formation of the first peptide bond. Pi: inorganic 
phosphate (Gebauer & Hentze, 2004). 
A 
B 
C 
D 
E 
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The 5’ cap-proximal region is recognized by eIF4F. This complex comprises the cap-
binding protein eIF4E; the DEAD-box RNA helicase eIF4A, which unwinds secondary 
structures in the 5’ untranslated region (5’UTR) so that the 43S complex can bind and 
scan the mRNA; and eIF4G, which functions as a ‘scaffold’ that binds eIF4E and eIF4A in 
order to form eIF4F, the cap-binding complex of translation initiation. The 43S complex 
then scans the 5′UTR in the 5′ to 3′ direction, downstream of the cap, until it finds the 
first AUG in good initiation context (fig 1. C) (scanning model of translation initiation; 
Kozak, 1989). The 43S complex recognizes the initiation codon through the formation 
of base pairs between the initiator tRNA and the start codon and formation of 48S 
initiation complex occurs (Jackson et al, 2010; Gebauer & Hentze, 2004). After 48S 
complex formation and initiation codon recognition, eIF5 promotes the hydrolysis of 
eIF2-bound GTP and eIF5B, a ribosome-dependent GTPase, and the displacement of 
eIFs and the joining of the 60S subunit (fig 1. D), leading to the assembly of 80S 
ribosome (fig 1.E), which is competent to initiate elongation. Although this is the 
canonical mechanism by which protein synthesis in eukaryotes occurs, there are some 
alternatives to this translation initiation model which may be cap-dependent (e.g. 
leaky scanning, reinitiation) or independent such as translation mediated by internal 
ribosome entry sites (IRESs) or CITEs among some other mechanisms that explain 
exceptions to this rule (Jackson et al, 2010; Gebauer & Hentze, 2004). 
 
I.1.2. Translation Elongation 
The end of the initiation process leaves an aminoacylated initiator tRNA in the P site of 
the ribosome and an empty A site, which serves to start the elongation cycle 
(Ramakrishnan, 2002). The elongation phase of protein synthesis involves the correct 
decoding of the mRNA into the amino acid sequence of the encoded polypeptide, 
involving fewer factors than initiation. A major feature of elongation must therefore be 
to maintain the accuracy of the process, to ensure errors are not made in synthesising 
the product (Proud, 1994). 
During elongation, amino acids are added sequentially to the growing polypeptide 
chain, in the order specified by the sequence of the mRNA in frame with the AUG 
codon. A key factor in this process is eukaryotic elongation factor eEF1A, which is 
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responsible for delivering the aminoacyl-tRNA to the A-site of the ribosome. The 
activity of eEF1A is dependent on GTP; the guanine nucleotide-exchange factor eEF1B 
promotes the regeneration of active eEF1A–GTP complexes. The last elongation factor 
is eEF2, which is required for the translocation of the peptidyl-tRNA from the A-site of 
the ribosome to the P-site and the movement of the ribosome along the mRNA. This is 
also a GTP-dependent process (fig 2) (Abbot & Proud, 2004). 
 
Figure 2: Model of the eukaryotic translation elongation pathway. Starting at the top, an 
eEF1A-GTP-aminoacyl-tRNA ternary complex binds the aminoacyl-tRNA to the 80S ribosome 
with the anticodon loop of the tRNA in contact with the mRNA in the A-site of the small 
subunit. Following release of eEF1A-GDP, the aminoacyl-tRNA is accommodated into the A 
site, and the eEF1A-GDP is recycled to eEF1A-GTP by the exchange factor eEF1B. Peptide bond 
formation is accompanied by transition of the A- and P-site tRNAs into hybrid states with the 
acceptors ends of the tRNAs moving to the P and E sites, respectively. Binding of eEF2-GTP 
promotes translocation of the tRNAs into the P and E sites, and is followed by release of eEF2-
GDP. The ribosome is now ready for the next cycle of elongation with release of the deacylated 
tRNA from the E site and binding of the appropriate eEF1A-GTP.aminoacyl-tRNAto the A-site. 
GTP: depicted as a green ball; GDP: depicted as a red ball (Dever & Green, 2012) 
 
 
The process of elongation is repeated many times, until a stop codon is reached. An 
additional amino acid is added to the growing polypeptide chain each time the mRNA 
advances through the ribosome. Once a polypeptide chain of reasonable size is 
assembled, it begins to emerge from the base of the large subunit (Klug et al, 2005). 
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When a stop codon is recognized by the ribosome, translation terminates, and the 
nascent protein must be released from the mRNA and ribosome (Clancy & Brown, 
2008).  
 
I.1.3. Translation Termination 
The final step of translation - termination - takes place when a stop codon, UAG, UAA, 
or UGA, enters the A-site of the ribosome. For simplicity, termination can be thought 
of as two distinct steps, stop codon recognition and peptide release. In eukaryotes, 
translation termination is mediated by eukaryotic release factor 1 (eRF1), which is 
responsible for stop codon recognition and triggering peptide release, and eRF3, a 
GTPase that stimulates eRF1-mediated peptide release (Abbot & Proud, 2004). eRF1, in 
turn, stabilizes binding of GTP to eRF3 so that they form a stable ternary complex 
(Mitkevich et al, 2006; Pisareva et al, 2006). The binding of the eRF complex to the 
ribosome stimulates the cleavage of the bond between the peptide and the tRNA, 
thus, releasing the newly synthesized peptide and the tRNA from the ribosome, which 
then dissociates into its subunits. If a stop codon should appear in the middle of an 
mRNA molecule, the same process occurs, and the polypeptide chain is prematurely 
terminated (Abbot & Proud, 2004; Klug et al, 2005; Dever & Green, 2012; Karijolich & 
Yu, 2014). Interactions of the eRFs with cellular proteins playing key roles in other gene 
expression processes may be the reason by which termination activity is adjusted and 
linked to other events in mRNA translation and NMD (fig 3) (Dever & Green, 2012). 
 
Figure 3: Model of eukaryotic translation termination. A complex comprised of eRF1 and eRF3 
mediate translation termination. eRF1 recognizes any of the three stop codons (UAA, UAG, 
UGA) in the ribosomal A site. GTP hydrolysis by eRF3 assists: 1) stop codon recognition by 
eRF1, and 2) eRF1 accommodation into the peptidyl transferase center so polypeptide release 
can occur (Keeling et al, 2012). 
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I.2. Nonsense-mediated mRNA decay - a surveillance mechanism 
At the level of mRNA, two important features are monitored by cell quality control 
mechanisms: first, whether it has the correct set of proteins bound to a particular 
mRNA; and, secondly, whether the coding potential of the mRNA is intact (Nicholson & 
Mühlemann, 2010).  
There are several quality control mechanisms in mammalian cells such as nonsense-
mediated mRNA decay (NMD), no-go mRNA decay and nonstop mRNA decay. Here, we 
are going to focus on NMD seen as it is the best characterized of the three and the only 
one studied in any detail from a regulatory perspective (Schoenberg & Maquat, 2012). 
NMD is one of the best characterized eukaryotic mRNA quality control mechanisms. 
NMD targets mRNAs harbouring premature termination (nonsense) codons (PTCs) for 
degradation. This pathway is important because if PTC-containing messages were 
allowed to be translated they would produce potentially toxic truncated proteins with 
potentially deleterious gain-of-function or dominant-negative activity (Nicholson & 
Mühlemann, 2010; Behm-Ansmant et al, 2007; Chang et al, 2007; Nicholson et al, 
2010).  
All organisms require the NMD pathway to eliminate transcripts containing PTCs, 
which arise from inherited or sporadic mutations or alternative splicing, so that normal 
cellular function is maintained; and to eliminate endogenous error-free transcripts in 
order to maintain regular levels of transcript and subsequent protein synthesis for 
development and viability (Chapin et al, 2014). 
 
I.2.1. PTC recognition 
Even before the identification of the NMD molecular players, a rule for the recognition 
of PTCs that induce mammalian NMD was postulated. Studies in mammalian systems 
led to the observation that PTCs, when located more than 50-54 nucleotides upstream 
the last exon-exon junction, were able to target mRNA for decay, whereas PTCs 
located downstream of this boundary do not induce NMD. The discovery of the exon 
junction complex provided a molecular explanation for the empirically detected ’50-54 
nucleotide boundary’ and supports the view that PTC recognition is dependent on the 
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definition of the exon-exon junctions, suggesting that the process of splicing is 
implicated in mammalian NMD (Silva & Romão, 2009; Schweingruber et al, 2013). 
A major issue that is still only partially understood is how NMD machinery 
distinguishes between premature and normal stop codons. Generation of a PTC can 
involve as little as a single nucleotide change. How such a subtle alteration can be 
detected as aberrant has led to several models. In all models, detection is intimately 
connected to translation termination. Synthesized mRNAs are bound by the cap-
binding protein heterodimer CBP80-CBP20, which constitutes the cap-binding complex 
(CBC), and if derived from intron-containing pre-mRNA, they are also bound by 
multiprotein assemblies, the EJCs, that presently are known to assemble ~20-24 nts 
upstream of each exon-exon junction during pre-mRNA splicing. The EJC contains the 
general splicing activator RNPS1, the RNA export factor Aly/ REF, the shuttling protein 
Y14, the nuclear matrix-localized serine-arginine-containing protein SRm160, the 
oncoprotein DEK, and the Y14 binding protein magoh. The interaction of magoh with 
Y14 may have a role in anchoring the NMD-specific factors UPF3 and UPF2 to the 
mRNA. Translation termination, which involves eRF1 and eRF3, provides the first signal 
necessary for activation of NMD. According to the present models, translating 
ribosomes displace EJCs from the open reading frame (ORF) during the “pioneer” 
round of translation. If assembly of eRF1-eRF3 at a termination codon occurs ≥ 50-54 
nucleotides (nts) upstream from an exon-exon junction, the footprint of the 
terminating ribosome is insufficient to physically remove the EJCs (Chang et al, 2007; 
Popp & Maquat, 2013; Inácio et al, 2004; Silva & Romão, 2009). The retained EJC(s) can 
interact with the translation termination complex via bridging interactions between 
the release complex-associated proteins, UPF1 and SMG-1 (Kashima et al, 2005). This 
bridging interaction has been proposed to trigger accelerated decay (i.e. NMD) of the 
PTC-containing mRNA (Peixeiro et al, 2011). 
 
I.2.2. Molecular events that prepare mRNA for degradation by 
NMD 
Translation termination is triggered by recognition of the stop codon by eRF1 and 
eRF3. The central feature of the “unified model” of NMD is that the mechanism of 
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translation termination at a PTC is intrinsically different from translation termination at 
a “correct” termination codon. In Saccharomyces cerevisiae, it has been demonstrated 
that ribosomes do not efficiently dissociate from the mRNA when stalling at a PTC, 
presumably because in that special environment they cannot receive the termination-
stimulating signal from Poly(A)-binding protein (PABP). Likewise, in flies and human 
cells, artificial tethering of PABP into close proximity of an otherwise NMD-triggering 
PTC efficiently suppresses NMD. Based on reported biochemical interactions, this 
model proposes that the decision of whether NMD is triggered relies on a competition 
between UPF1 and PABP for binding to eRF3 bound to the terminating ribosome. 
According to this model, a translation termination event is defined as “correct” if the 
ribosome stalls close enough from the poly(A) tail to efficiently interact with PABP, 
which, through yet unknown mechanisms, leads to a fast/efficient polypeptide release 
and dissociation of the ribosomal subunits. If, in contrast, the spatial distance between 
the terminating ribosome and the poly(A) tail is too big for this interaction to occur, 
UPF1 will bind to the ribosome-bound eRF3 instead. Using co-immunoprecipitation 
analysis, a recent study showed that UPF1, eRF1, and eRF3 are part of a single complex 
that also contains the UPF1 kinase Suppressor with Morphogenetic effect on Genitalia-
1 (SMG1) (Kashima et al, 2006). This SMG1 - UPF1 - eRF1 - eRF3 (SURF) complex is 
proposed to assemble on ribosomes stalled at a stop codon, with eRF1 and eRF3 
recruiting unphosphorylated UPF1, which in turn recruits SMG1. At this stage, UPF1 
might still be displaced by PABP and NMD would be prevented. However, when this 
signal is absent, UPF2 and UPF3 will eventually bind UPF1, forming the decay-inducing 
complex (DECID), which is required for SMG1 to phosphorylate UPF1. UPF1 
phosphorylation is believed to definitively commit the mRNA for degradation by NMD, 
maybe by inducing a conformational change that causes UPF1 to bind the mRNA. 
Finally, the phosphorylated UPF1 will be bound by the 14-3-3-like phosphoserine-
binding domains of SMG5, SMG6 and/or SMG7, ultimately leading to the degradation 
of the mRNA. Phosphorylation of UPF1 triggers a critical step of translational 
repression that is required before the messenger ribonucleoprotein particle (mRNP) 
can be degraded. This step involves an interaction between phosphorylated UPF1 and 
eIF3 that is part of the 43S ribosomal complex at the initiation codon of an NMD 
target. This interaction inhibits 60S ribosomal subunit joining to form a translationally 
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active 80S ribosome and thus further translation initiation events on the mRNP (Chang 
et al, 2007; Mühlemann et al, 2008; Schweingruber et al, 2013; Popp & Maquat, 2013). 
Finally, the phosphorylated UPF1 will be bound by the 14-3-3-like phosphoserine-
binding domains of SMG5, SMG6 and/or SMG7, ultimately leading to the degradation 
of the mRNA (Mühlemann et al, 2008). 
 
I.2.3. NMD degradation mechanism 
Although good progress has been made in the understanding of the PTC-recognition 
mechanism, little is known about the subsequent degradation of the recognized 
nonsense mRNA. Current models propose that the factors SMG5, SMG6 and SMG7 are 
involved in this process through SMG5/SMG7-mediated exonucleolysis and interaction 
of SMG6 with phospho-UPF1 leads to a SMG6-mediated endonucleolytic cleavage near 
the aberrant termination site (fig 4) (Nicholson & Mühlemann, 2010; Nicholson et al, 
2010). 
A common concept in metazoan NMD seems to be that phosphorylated UPF1 induces 
various mRNA decay activities by recruiting decay factors or adaptor proteins for decay 
complexes through its N- and C-terminal phosphorylation-sites (Schweingruber et al, 
2013).  
During NMD, mRNAs containing a phosphorylated UPF1 are committed to destruction. 
Subsequent interaction of UPF1 with UPF2 and UPF3 directs SMG1-mediated 
phosphorylation of UPF1, which in turn recruits SMG5, SMG7 and/or SMG6, which has 
endonucleolytic activity in its PIN (PilT N-terminal) domain. Finally, this leads to SMG6-
mediated endocleavage near the PTC (Eberle et al, 2008). Irreversible endonucleolytic 
cleavage by SMG6 generates a 5’ cleavage product that includes the PTC and a 3’ 
cleavage product that contains the EJC and NMD components. The 5’ cleavage product 
is subject to 3’ to 5’ decay, possibly by the exosome, or to alternative decay pathways 
involving degradation from either of the RNA termini (Popp & Maquat, 2013), such as 
deadenylation-independent, and endonucleolytic cleavage dependent decay 
(Mühlemann et al, 2008). 
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Irreversible endonucleolytic cleavage by SMG6 generates a 5’ cleavage product that 
includes the PTC and a 3’ cleavage product that contains the EJC and NMD 
components. The 5’ cleavage product is subject to 3’ to 5’ decay, possibly by the 
exosome. The 3’ cleavage product must meanwhile be stripped of its protein 
components in order to be accessible to nucleases, and this is the job of UPF1. UPF1 
activity is normally auto-inhibited by its own N- and C-terminal domains, but when 
UPF1 binds to UPF2, it undergoes a large conformational change that activates its 
helicase activity. UPF1 helicase activity disassembles proteins bound to the 3’ cleavage 
product, recycling NMD factors and facilitating 5’ to 3’ exonucleolytic degradation by 
the exoribonuclease XRN1 following 5’ cap removal by DCP2 initiated by the NMD 
factors. Phosphorylated UPF1 also recruits SMG5, an adaptor that binds either proline-
rich nuclear receptor 2 (PNRC2) or SMG7, each of which in turn recruits activities that 
result in mRNA decapping followed by 5’ to 3’ degradation, deadenylation followed by 
3’ to 5’ degradation, or both (Popp & Maquat, 2013; Nagarajan et al, 2013). This 
pathway of deadenylation-dependent RNA decay represents the major decay 
mechanisms for RNA-turnover in the cytoplasm (Nagarajan et al, 2013). 
Research carried out in S. cerevisiae suggests that nonsense mutated mRNAs are 
rapidly degraded using the main mRNA-turnover pathway as outlined above with a 
modification thereof that is typified by deadenylation-independent decapping and 
XRN1-mediated 5’ to 3’ exonucleolytic decay. In mammalian cells, studies have shown 
that nonsense mutated mRNAs can be degraded via the conventional mRNA-turnover 
pathway, starting with deadenylation, followed by decapping and XRN1-mediated 
exonucleolytic decay (Nicholson & Mühlemann, 2010; Nicholson et al, 2010). Further 
work is required to determine the relative contributions of the two decay pathways 
involved in mammalian NMD and to understand what determines which decay route is 
taken by the different types of mRNAs directed to the NMD pathway (Nicholson & 
Mühlemann, 2010). 
 
12 
 
 
Figure 4: Model for degradation of NMD substrates. The model posits that UPF1-bound 
mRNAs can be degraded by two different pathways, depending on whether the SMG-5/SMG-7 
heterodimer or the endonuclease SMG-6 binds to phosphorylated UPF1. Interaction of SMG-5/ 
SMG-7 with phospho-UPF1 promotes deadenylation followed by decapping and exonucleolytic 
RNA decay from both ends (left branch). Interaction of SMG-6 with phospho-UPF1 leads to a 
SMG6-mediated endonucleolytic cleavage near the aberrant termination site, followed by the 
exonucleolytic degradation of the two RNA fragments from the initial cleavage site (Nicholson 
et al, 2010). 
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I.2.4. NMD targets 
NMD is one of a number of mammalian-cell mRNA decay pathways that is coupled to 
the translation of its target. Regulators of translation must be considered regulators of 
NMD (Schoenberg & Maquat, 2012). The discovery that not only the initially identified 
PTC-containing mRNAs but also many PTC-less mRNAs are targeted by NMD (re-)posed 
the question, which features render an RNA susceptible to NMD and pointed out our 
limited understanding of the mechanism of substrate selection (Schweingruber et al, 
2013). 
Until a few years ago, NMD has been seen merely as a quality control system that rids 
the cell of faulty mRNAs, but recent studies indicate that NMD represents a much 
more sophisticated tool serving multiple purposes in gene expression. The population 
of NMD substrates is not only restricted to faulty transcripts, but also comprises 
numerous endogenous, physiological transcripts. Among those are: i) mRNAs 
containing short upstream ORFs (uORFs) were the termination codon of the uORF is 
likely to be interpreted as PTC, unless the mRNA harbours stabilizing elements nearby; 
ii) mRNAs encoding selenocysteine-containing proteins were UGA can be recognized as 
codon for selenocysteine or as PTC, depending on endogenous selenium 
concentration; iii) mRNAs harbouring introns in their 3’ UTR; iv) mRNAs with long 
3’UTRs, which, in experimental situations generally make transcripts sensitive to NMD; 
and v) transposons and retroviruses, likely due to indirect effects of NMD pathway 
disruption. In addition, pseudo-genes, bicistronic mRNAs, and mRNAs containing 
signals for programmed frameshifting have been identified as NMD targets in yeast. 
NMD acts on them because their termination codons can be interpreted as a PTC 
(Mühlemann et al, 2008; Chapin et al, 2014).  
 
I.2.5. Implication of NMD in disease 
Nonsense mutations account for ~11% of all gene lesions known to cause human 
inherited disease and ~20% of disease-associated single-base pair substitutions 
affecting gene coding regions (Mort et al, 2008). 
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There are numerous examples of human diseases associated with mutations that 
result in PTCs. If translated, the PTC-containing mRNAs would give rise to truncated 
proteins that have either completely lost their function, are still functional, have 
acquired dominant-negative function or have gained new functions. As a consequence 
of these different possibilities, NMD has a double-edged effect on the manifestation of 
a disease: NMD can act either in a beneficial or in a detrimental way; the former if it 
prevents the synthesis of toxic truncated proteins and the latter if it prevents the 
production of proteins with some residual function. Thus, NMD represents a crucial 
modulator of the clinical outcome of many genetic diseases (Nicholson et al, 2010; 
Nicholson & Mühlemann, 2010).  
There are many well-studied examples of human phenotypes resulting from nonsense 
or frameshift mutations that are modulated by NMD. The phenotypes of genetic 
diseases are likely to be frequently affected by NMD as PTCs are present in 
approximately one-third of the human genetic disorders (Khajavi et al, 2006). 
The majority of PTC-containing disease-associated alleles exert their negative effects 
due to insufficient production of a functional protein. An example where NMD 
aggravates the clinical outcome is provided by several disease phenotypes caused by 
mutations in the dystrophin gene. While most of the truncating mutations in the 
dystrophin gene are associated with a similar phenotype, the rare truncating 
mutations that occur near the 3’ end of the dystrophin gene can result in extremely 
variable phenotypes. It has been suggested that all truncated proteins encoded by 
genes with mutations near the 3’ end would in theory be capable of rescuing the 
Duchene’s Muscular Distrophy phenotype, but when NMD prevents their synthesis, 
the clinical manifestations of the disease are aggravated. Conversely, NMD has a well-
documented beneficial role in the degradation of PTC-containing β-globin mRNA, 
thereby preventing the synthesis of C-terminally truncated β-globin that would 
otherwise cause toxic precipitation together with surplus α-globin chains. In a 
heterozygote context, the second wild-type allele supports almost normal levels of β-
globin synthesis, contributing to the correct haemoglobin assembly, which is reflected 
in the recessive inheritance of this β-thalassaemia type. However, rare NMD-
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insensitive PTCs are responsible for the dominant form of β-thalassaemia (Nicholson et 
al, 2010). 
 
I.2.6. β-Thalassaemia as a model disease for studying NMD 
β-thalassaemia is one of the most common genetic diseases worldwide (Higgs et al, 
2012). β-Thalassaemias are a heterogeneous group of inherited human anaemia’s 
characterized by reduced or absent β-globin chain synthesis, resulting in reduced 
haemoglobin in red blood cells, decreased red blood cells production and anaemia. 
They are attributed to mutations within or upstream of the β-globin gene. The majority 
of these mutations are frameshift or nonsense mutations, which are the most 
prevalent β-globin mutations that cause β-thalassemia, within an exon that have no 
effect on gene transcription or RNA splicing but result in the premature termination of 
β-globin mRNA translation (Lim et al, 1989; Galanello & Origa, 2010; Peixeiro et al, 
2011).  
The major molecular consequences of stop mutations are the promotion of premature 
translational termination and NMD. NMD will therefore prevent the production of 
truncated and faulty proteins, which if failed could result in the synthesis of abnormal 
proteins that can be toxic to cells through dominant-negative or gain-of-function 
effects. This nonsense mediated mRNA decay has been found in bacterial, yeast, plant 
and mammalian cells. It has been proposed that in the human β-globin gene, 
mutations causing translation premature termination in exons 1 and 2 result in a 
decrease of the mRNA from the affected allele, causing a 50% reduction of total β-
globin chain synthesis in the heterozygote (Romão et al, 2000; Salvatori et al, 2009a). 
In β39-thalassaemia the CAG (glutamine) codon of the β-globin mRNA is mutated to 
the UAG stop codon, leading to premature translation termination and to mRNA 
destabilization through the well-described NMD. Other examples of stop mutations of 
the β-globin mRNA occur at positions 15, 37 and 127 of the mRNA (Salvatori et al, 
2009a). In contrast, results obtained by Romão et al, 2000 from the study of nonsense-
mutated mRNA at codons 5, 15 or 17 indicate that the human β-globin mRNA carrying 
a nonsense mutation in the 5’ half of exon 1 escapes NMD, the AUG-proximity effect. 
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On the other hand, if a PTC is localized in the last exon of the β-globin gene, the 
transcripts produced are NMD-insensitive and are translated into truncated proteins 
with dominant negative effects, as is the case of the stop mutation at position 127 
(Mühlemann et al, 2008; Salvatori et al, 2009a). 
The fact that nonsense mutations promote premature translational termination and 
are the leading cause of up to 30% of inherited diseases, one of them being 
thalassemia, and given the small size of the β-globin gene and the wide range of 
nonsense mutations that have been described at this locus make this disease an 
attractive model for investigating the effects of premature translation termination on 
mRNA metabolism (Salvatori et al, 2009b; Romão et al, 2000). 
I.2.7. Suppression therapy 
For many genetic disorders caused by PTC-generating mutations, there are no effective 
treatments available. Because NMD plays an important role in modulating the clinical 
manifestations of such diseases, interfering with NMD represents a promising 
therapeutic strategy. For those cases where the truncated protein is still functional, 
inhibiting rapid degradation of the nonsense mRNA would in principle suffice to 
elevate the protein concentration and ameliorate the condition of patients. However, 
in most cases, production of the full-length protein would be necessary to restore 
function, which can be achieved by promoting readthrough of the PTC (Mühlemann et 
al, 2008). When a stop codon enters the ribosomal A-site, the sampling process is 
initiated just as it does at a sense codon. Near-cognate aminoacyl tRNAs with 
anticodons that are complementary to two of the three nucleotides of a stop codon 
can compete with the release factors for A-site binding. Normally, stop codon 
recognition by the eRF1/3 complex efficiently out-competes near-cognate aminoacyl 
tRNAs and efficient polypeptide chain release occurs. On occasion, aminoacyl tRNAs 
that are near-cognate to a stop codon become accommodated in the ribosomal A-site 
and their amino acid is incorporated into the polypeptide. This process that recodes a 
stop codon into a sense codon is referred to as a “readthrough” event. PTC 
readthrough suppresses translation termination and allows translation elongation to 
continue in the correct reading frame until the normal stop codon is encountered 
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(Keeling & Bedwell, 2011). Given that the presence of PTCs codons explain one third of 
all described inherited human diseases (Bhuvanagiri et al, 2010), therapeutic strategies 
aimed at suppressing nonsense codons (so-called nonsense suppression therapies) 
have the potential to provide a therapeutic benefit for patients with a broad range of 
genetic diseases (Keeling et al, 2014; Keeling & Bedwell, 2011). 
The goal of suppression therapy is to enhance the ability of near-cognate aminoacyl 
tRNAs to compete with the release factor complex for binding PTCs in the ribosomal A 
site. By increasing the frequency that PTCs are recoded into sense codons, enough full 
length, functional protein may be restored to provide a therapeutic benefit to patients 
that carry PTC containing transcripts (Keeling & Bedwell, 2011). In the last few years, it 
has been demonstrated that drugs can be designed and produced to suppress 
premature termination, inducing a ribosomal readthrough of PTCs in eukaryotic 
mRNAs. In order to develop an efficient suppression therapy, aminoglycoside 
antibiotics, including gentamicin, amikacin, paromomycin, geneticin (G418), 
lividomycin, tobramycin, and streptomycin have been tested on mRNAs carrying PTCs 
and shown to suppress disease-causing PTCs in mammalian cells. These drugs bind the 
decoding centre of the ribosome and decrease the accuracy in the codon-anticodon 
base-pairing, inducing a ribosomal readthrough of premature termination codons 
partially restoring protein function to various extents for more than twenty different 
disease models in vitro, and eight different disease models in vivo (Mühlemann et al, 
2008; Salvatori et al, 2009a; Salvatori et al, 2009b; Keeling & Bedwell, 2011). 
However, though these results are promising there are still several obstacles that must 
be overcome before aminoglycosides can be used long-term in the suppression of 
nonsense mutations. First, the efficiency of suppressing PTCs is greatly influenced by 
the identity of the stop codon and the surrounding mRNA sequence. Various 
aminoglycosides have different abilities to suppress PTCs. This suggests that screening 
compounds to identify those that best suppress a particular PTC in its natural sequence 
context is needed. Second, the long-term use of aminoglycosides is limited due to side 
effects and not all patients respond in the same way to these drugs which could 
possibly be due to the different efficiencies of NMD, from individual to individual 
(Keeling & Bedwell, 2011; Welch et al, 2007). 
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I.3. Aims 
It has been estimated that about 1.5% of the global population (80 to 90 million 
people) are carriers of β-thalassemia, with about 60,000 symptomatic individuals born 
annually, the great majority in the developing world (Galanello & Origa, 2010). The 
majority of the mutations associated with β-thalassemia are nonsense mutations 
which result in the premature termination of β-globin mRNA translation and 
consequently NMD (Galanello & Origa, 2010; Peixeiro et al, 2011). Therefore, it would 
be of great interest that these nonsense mutations in the β-globin gene could be 
suppressed with the use of drugs such as aminoglycosides. Preliminary results 
obtained in our lab had shown that the aminoglycoside G418 can suppress a PTC at 
codon 39 of the human β-globin mRNA, although at low levels in cultured erythroid 
cells. The aim of the work carried out in this thesis was to further prove that 
suppression therapy can restore enough β-globin protein and therefore correct the 
disease manifestations of β-thalassemia. In this regard, it was decided to test whether 
G418 is able to induce efficient levels of suppression in a dose-dependent and time-
course manner in HeLa cells transfected with plasmids containing the wild type (βWT) 
or β39 human β-globin genes. 
II. Methods 
II.1 Plasmid constructs  
The plasmids containing βWT (wild type version of the β-globin gene), β15 (with 
mutation at codon 15) [CD 15 (TGG→TGA)], or β39 (with mutation at codon 39) [CD 39 
(CAG→TAG)] human β-globin gene were obtained as previously described in Romão et 
al, 2000. All variants were created within the 428-bp NcoI-BamHI fragment of the β-
globin gene template by overlap-extension PCR. Competent Escherichia coli were 
transformed with the plasmid DNA, and transformants were selected on luria-bertani 
(LB) agar/ampicillin plates. The corresponding plasmid DNAs were purified from 
overnight cultures of single colonies with the NZYMini prep kit (NZYTech, Portugal) 
following the manufacturer’s instructions. Confirmation of the correct cloned 
sequences containing the relevant mutation was carried out by automatic sequencing. 
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II.2 Cell culture and plasmid transfections 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM 1x + 
GlutaMAXTM-I; Gibco® by Life Technologies™, USA) supplemented with 10% (v/v) 
foetal bovine serum (FBS; Gibco® by Life Technologies™, USA), incubated at 37°C in a 
humidified atmosphere of 5% CO2.  
Transient transfections were performed using Lipofectamine 2000 Transfection 
Reagent (Invitrogen® by Life Technologies™, USA), following the manufacturer’s 
instructions, in 35-mm plates containing HeLa cells plated 24h prior to transfection, 
using 400 ng, of plasmid DNA of each variant (βWT, β15 and β39). Twenty-four hours 
post-transfection, cells were either treated or untreated with G418 (Sigma-Aldrich®, 
USA). The culture medium was removed and new medium supplemented with 0 
µg/ml, 50 µg/ml or 200 µg/ml of G418 (Sigma-Aldrich®, USA) was added. The medium 
was not changed during the treatment period. Cells were harvested 12h and 24h post 
treatment with the above mentioned drug by rinsing twice with Phosphate Bufferd 
Saline (PBS) and lysed via solubilisation in Passive Lysis Buffer (PLB; Promega, USA).  
 
II.3 RNA isolation 
Total RNA from cultured HeLa cells was isolated using the RNA extraction kit 
NucleoSpin RNA II (Macherey-Nagel, Germany) according to the manufacturer’s 
instructions. RNA samples were treated with RNase-free DNase I (Ambion® by Life 
Technologies™, USA) and purified by phenol-chloroform extraction.  
 
II.4 Reverse transcription-coupled quantitative PCR (RT-qPCR) 
cDNA synthesis was carried out using 2 μg of total RNA and Reverse Transcriptase 
(NZYTech, Portugal), according to the manufacturer’s instructions. Real-Time 
quantitative PCR (RT-qPCR) was performed in ABI Prism 7000 Sequence Detection 
System, using SybrGreen Master Mix (Applied Biosystems® by Life Technologies™, 
USA). Primers specific for the gene of interest, β-globin (primer forward 5’-
GTGGATCCTGAGAACTTCAGGCT-3’ and primer reverse 5’-CAGCACACAGACCAGCACGT-
3’) and for the control, puromycin resistance gene (primer forward 5’-
20 
 
GGGTCACCGAGCTGCAAGAA-3’ and primer reverse 5’-CACACCTTGCCGATGTCGAG-3’) 
were designed. Quantification was performed using the relative standard curve 
method (ΔΔCt, Applied Biosystems® by Life Technologies™, USA). The following cycling 
parameters were used: 10 min at 25°C and then 50°C for 30 min and 5 min at 85°C. 
Technical triplicates from each experiment were assessed in all cases. 
 
II.5. SDS-PAGE and Western blotting 
Cells lysates were denatured for 10 minutes at 65°C. Five µl of SDS sample buffer 5x 
[Bromophenol blue (0.25%), DTT (dithiothreitol; 0.5 M), Glycerol (50%), SDS (sodium 
dodecyl sulfate; 10%), Tris-Cl (0.25 M, pH 6.8)] was added to 20 µl of purified lysates 
and these were loaded in to a 12% polyacrylamide gel and resolved for 1 hour. After, 
they were transferred to a PVDF membrane (Bio-Rad, USA) for 1 hour. The membrane 
was blocked in 5% (w/v) nonfat dry milk for 1 hour and probed using mouse anti-α-
tubulin antibody (loading control; Roche, Switzerland) at 1:10 000 dilution and mouse 
monoclonal anti-β-globin (Santa Cruz Biotechnology, USA) at 1:200 overnight. After 
incubation with the primary antibody, membranes were washed 3 times in TBS-Tween 
20 (Sigma-Aldrich®, USA) 0.05% (v/v) and 0.1% (v/v). Detection was carried out by 
incubating the membranes for 1 hour with the secondary antibodies, peroxidise-
conjugated anti-mouse IgG (Bio-Rad, USA), anti-rabbit IgG (Bio-Rad, USA) antibodies, 
followed by enhanced chemiluminescence reaction. 
Seen as we were unable to detect protein, optimizations had to be made to the 
protocol. We first altered the dilution of the mouse monoclonal anti-β-globin, the 
concentration of TBS-Tween 20 was lowered, the washing times were also altered and 
finally the exposure times were increased. We will further discuss these alterations in 
point III.2.2. 
 
II.6. Statistical analysis 
Results are expressed as mean ± standard deviation of 3 experiments in which the 
mRNA levels expressed from β15 and β39-containing plasmids are normalized to the 
wild type mRNA levels arbitrarily set to 1. Student’s t test was used for estimation of 
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statistical significance (unpaired, two tails). Significance for statistical analysis was 
defined as a p< 0.05 (Livak & Schmittgen, 2001). 
 
III. Results and Discussion 
 
III.1. Sequence analysis of the plasmid DNAs encoding the β-globin 
gene 
The aim of this study was to prove that suppression therapy by treatment with G418 
can restore correct β-globin protein. For this purpose, we chose to transiently express 
a plasmid encoding the β-globin gene in HeLa cells and check the levels of expression 
of this gene in the presence or absence of a drug that promotes readthrough of a PTC. 
For that, we used, alongside the wild type version of the gene, two other versions: one 
with a nonsense-mutation in codon 15, which is imminent to NMD, due to the AUG-
proximity effect (Silva et al, 2008); and one version of the gene carrying a nonsense 
mutation in codon 39, which is typically committed to NMD (Romão et al, 2000). In 
order to check if we were using the plasmids expressing the correct versions of the 
gene, we sequenced the previously obtained plasmids (Romão et al, 2000) to confirm 
the presence of the mutation in codon 15 and 39 and the correct sequence in wild-
type. Sequence analysis of the amplified plasmids encoding the β-globin gene (wild-
type, with mutation at codon 15 and with mutation at codon 39) confirmed the 
presence of a mutation at codon 15 (TGG→TGA) or 39 (CAG→TAG) (fig 5). In addition, 
sequence analysis of the βWT gene did not reveal any mutation (fig. 5). 
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Figure5: Sequencing analysis confirmed the presence of nonsense mutations that originated 
a stop codon at codons 15 and 39 of the β-globin gene, respectively. The chromatogram of 
the amplified wild type β-globin gene-containing plasmid DNA is shown on the left in order to 
compare to the sequencing reaction of the amplified plasmid DNA containing the β15 gene (A) 
shown on the right and the β39 gene (B) shown also on the right. Underlined sequences 
indicate codon 15 (A) and codon 39 (B). N indicates that the algorithm is unable to identify the 
base. Even though this happens, due to a very low cut-off, it is still possible to identify which 
base is because the peek is very clear.  
 
III.2. Analysis of βWT, β15 and β39 transcripts in transiently 
transfected HeLa cells  
As mentioned above, it has previously been shown that transcripts carrying mutations 
in exon 1 of the human β-globin gene (namely at codon 15) are expressed at levels 
approaching those of the wild-type β-globin mRNA in erythroid cells, which means that 
this AUG-proximal nonsense-mutated gene escapes NMD (Silva et al, 2008). On the 
other hand, those at positions downstream of codon 24, such as β39 transcripts, are 
expressed at low levels indicating that they undergo fully efficient decay (Romão et al, 
2000). As these mutations have been proven to have β-thalassaemia clinical relevance 
we analysed whether these mutations causing premature translation termination 
could be suppressed in HeLa cells with the use of aminoglycosides. For that, we 
transiently transfected HeLa cells with the plasmids carrying the βWT, β15 or β39 
genes. Twenty-four hours later cells were harvested and protein and RNA were 
isolated for analysis.  
B βWT β39 
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III.2.1. mRNA quantification by RT-qPCR analysis  
The relative mRNA levels were quantified by RT-qPCR and normalized to the level of 
the βWT mRNA (arbitrarily set to 100%) (fig 6). Results show that β15 relative mRNA 
level is 70% of the βWT mRNA. In contrast, the level of β39 mRNA indicates that rapid 
decay has occurred: 31% of βWT mRNA.  
 
 
 
 
 
 
 
 
Figure 6: RT-qPCR analysis confirms that the transcript containing the mutation at codon 39 
is degraded via NMD. (A) Representative RT-qPCR analysis of RNA isolated from untreated 
HeLa cells transiently transfected with the constructs specified beneath each lane. Resulting 
mRNA levels were normalized to the expression level of the wild-type mRNA. 0 represents 
non-transfected HeLa cells which serves as negative control of the transfection efficiency as 
these cells are not able to express the β-globin gene endogenously. C-βWT corresponds to the 
reverse transcription reaction without the reverse transcriptase enzyme which serves as a 
control to detect the presence of DNA contamination. 
 
These data were expected as they confirm what was previously reported by Romão et 
al, 2000 and Inácio et al, 2004 revealing that the tested β15 transcript with a PTC 
located upstream of codon 24 is able to escape NMD, producing mRNA levels similar to 
that of βWT, whereas the transcript mutated at a position downstream of codon 24, as 
is the case with β39, undergoes rapid decay through NMD. 
Transfected constructs 
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III.2.2. Protein analysis by Western Blot  
Western blot analysis of protein samples extracted from the cells transfected with 
each one of the plasmids was performed in order to evaluate protein levels produced 
by each transcript (fig 7). As one can observe in figure 5, as far as protein production is 
concerned, it was unable to detect any production of β-globin protein. This may be as 
a result of low signal visibility, consequence of low concentration of the antibody or 
antigen or prolonged washing, and the buffers used may also contribute to the 
problem. Therefore the conditions in which the Western blot was performed were 
optimized. Primary antibody dilution was altered from 1:200 to 1:100, increasing its 
concentration. Incubation time with the primary antibody was increased to intensify 
the signal. Even though β-globin is not a phosphorylated protein, Bovine Serum 
Albumine (BSA) was used to see if it produces any significant alteration in the 
detection of the protein. The stringency of the washing conditions was decreased. 
Finally, exposure times were increased from 1 s, 30 s, 1 min and 2 min, to 1 s, 1 min, 5 
min, 10 min, to achieve an optimum time. After various alterations to our initial 
protocol (based on manufacturer’s instructions) Western blot analysis was performed, 
yet different conditions were used, we were still unable to detect protein. It was 
hypothesized that this may be because the conditions in which the cells were kept may 
somehow cause them some stress inhibiting translation. However, this is not the case 
since it was able to detect α-tubulin, the loading control, a protein that is produced 
endogenously. If cells can produce this protein, the translation machinery is working. 
Also, α-tubulin is cap-dependent translated, so, a priori, no translation factor is 
missing. It was also hypothesized that the antibody may have not been produced 
properly. The ideal at this point would be to try a new antibody and if this wouldn’t 
work to try the antibody on a different cell line that produces the β-globin gene 
endogenously. Due to time and money contingencies, this was not feasible and 
therefore it was decided to continue the work studying the effect of the drug of choice 
(G418) only on the mRNA, while trying to understand why the antibody was unable to 
detect protein. This may possibly indicate some lines of evidence on the effect of the 
drug at mRNA level and produce some more knowledge regarding this matter.  
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Figure 7: Western blot analysis of cell lysates. The molecular weights of the α-tubulin (55 kDa) 
and β-globin (16 kDa) proteins are indicated on the right hand side of the autoradiograph. The 
very faint bands that can be seen in βWT and β39 are artifacts. 
 
III.3. Analysis of βWT and β39 transcripts in transiently 
transfected HeLa cells exposed to geneticin (G418) 
We transfected HeLa cells with plasmids expressing βWT and β39 genes. Twenty-four 
hours later, cell cultures were either treated or untreated with increasing 
concentrations (50 µg/ml or 200 µg/ml) of G418 and harvested 12 or 24 hours later. 
The β-globin mRNA levels were quantified by RT-qPCR analysis (fig 8). Results have 
shown that the relative mRNA level of the β39 transcript is approximately 40% of the 
βWT mRNA, which is arbitrarily set to 100% (fig.8A). These data indicate that these 
nonsense-mutated mRNAs undergo rapid decay, as expected. On the other hand β39 
mRNA levels of G418 treated cells is at similar levels (fig. 8B and C), although there is 
an increase  
 
 
 
 
 
 
 
βWT β15 0 β39 
α-tubulin (55kDa) 
β-globin (16 kDa) 
A 
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Figure 8: RT-qPCR analysis performed on RNA isolated from HeLa cells containing the βWT 
and β39 transcripts treated with increasing doses of G418 in a time-course manner. Panel A 
depicts an untreated control as cells were lysed 24-hours post-transfection and were not      
treated with any amount of G418. Resulting levels of relative mRNA levels are normalized to 
the expression level of the wild-type mRNA. Panels B and C depict treated cells with the 
indicated amounts of G418 for 12 hours and 24 hours, respectively.  
 
of 15% in β39 mRNA levels in the presence of 50 µg/ml of G418 and an increase of 25% 
in the presence of 200µg/ml of G418, compared to no treatment conditions (fig. 8 B); 
B 
C 
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at 24h, there is no change in mRNA levels in the presence of 50 µg/ml of G418, 
whereas in the presence of 200µg/ml of G418 it is possible to see an increase of 20% 
compared to control conditions (fig. 8 C). Although we observe an increase in β39 
mRNA levels upon treatment unfortunately it is not significant. The great standard 
deviations are due to the fact that the experiments all resulted in very different CT 
values. The observed increase may be due to the ability of the aminoglycoside to bind 
to the decoding centre of the ribosome leading to the reduction of translation fidelity 
by reducing the proofreading ability of the ribosome and increasing the 
misincorporation of near-cognate aminoacyl tRNAs into the ribosomal A site at stop 
codons, resulting in translational misreading at PTCs without premature termination of 
protein synthesis with concomitant NMD inhibition. However one can not be sure 
about this seen as it is not possible to see the effects of the drug on protein synthesis. 
Another possibility could be the ability of the drug to reduce the sensitivity of the NMD 
machinery to the presence of a PTC, which would be a side-effect of the drug. However 
it has been shown that this aminoglycoside, and various others, is capable of 
suppressing disease-causing PTCs in mammalian cells expressing genes carrying these 
mutations, without altering global protein or mRNA profiles (Keeling & Bedwell, 2011). 
 
IV. Future directions 
While the results regarding the steady increase of mRNA levels after treatment with 
G418 are promising, a previous report describes a promising drug, PTC124 by PTC 
Therapeutics, Inc., which is able to suppress nonsense mutations by a readthrough 
activity, as well as, or better than aminoglycosides, at nanomolar concentrations in  
mammalian cells without toxic side effects. This molecule is administered orally and is 
expected to be very promising in therapy. PTC124 has no structural similarity to 
aminoglycosides or other clinically developed drugs and was found to be safer offering 
therapeutic benefits to many patients (Keeling & Bedwell, 2011; Welch et al, 2007; 
Salvatori et al, 2009a). Given that this compound is currently undergoing clinical trials 
for several diseases (Keeling & Bedwell, 2011) and that thalassemia is a major health 
problem in developing countries (Salvatori et al, 2009a; Galanello & Orita, 2010), it 
C 
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would be of great interest to test this compound in its ability to suppress PTCs in the β-
globin gene in comparison with the effects of G418. It has also been shown that 
tethering PABPC1 in close proximity of a NMD-competent PTC inhibits NMD (Silva et al, 
2008; Behm-Ansmant et al, 2007). Based on these data we suggest testing if we could 
increase the efficiency of suppression therapy by transfecting cells with antisense 
oligonucleotides specific for the β-globin mRNA sequence but with a degenerated 
poly(A)  tail in combination with one of the drugs tested. Each oligonucleotide must 
have a poly(A) tail long enough to bind at least two PABPC1 molecules which will allow 
PABPC1 to bind and thus to inhibit NMD. The combination of these two treatments 
may give a promising and efficient therapy.         
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